Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1996-12-30
1998-06-23
Degen, Nancy
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
435 681, 530384, 530413, 530829, C07K 14745, C07K 118, A61K 3836, C12P 2106
Patent
active
057706999
ABSTRACT:
A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.
REFERENCES:
patent: 4285932 (1981-08-01), Smith
patent: 4318904 (1982-03-01), Shaw et al.
patent: 4337244 (1982-06-01), Smith
patent: 4447416 (1984-05-01), Menache-Aronson
patent: 4604285 (1986-08-01), Smith et al.
patent: 4721572 (1988-01-01), Jordan
patent: 4725673 (1988-02-01), Herring
patent: 5071961 (1991-12-01), Kraus et al.
patent: 5120537 (1992-06-01), Esmon et al.
patent: 5153166 (1992-10-01), Jain et al.
patent: 5153175 (1992-10-01), Krueger et al.
patent: 5278144 (1994-01-01), Wolf
patent: 5279956 (1994-01-01), Griffin et al.
patent: 5589571 (1996-12-01), King
patent: 5589572 (1996-12-01), King
patent: 5602233 (1997-02-01), King
Ahmad et al., "Rapid Purification of Factor IX, Factor X and Prothrombin by Immunoaffinity and Ion Exchange Chromatography," Thrombosis Research (1989)55:121-133.
Aronson et al., "Two Forms of the Human Prothrombin Converting Enzyme (Active Factor X) (35769)," Two Forms of X, (1971) 137:4, 1262-1266.
Bajaj et al., "A Simplified Procedure for Purificaion of Human Prothrombin, Factor IX and Factor X,"Preparative Biochemistry (1981) 11:4, 397-412.
Cassels et al., "The Interaction of Streptokinase Plasminogen Activator Complex Tissue-Type Plasminogen Activator, Urokinase and their Acylated Derivatives with Fibrin and Cyanogen Bromide Digest of Fibrinogen," Biochem. J. (1987) vol. 247, 395-400.
Chattopadhyay et al., "Molecular Recognition in the Activation of Human Blood Coagulation Factor X, " The Journal of Biological Chemistry, (1989)264:19, 11035-11043.
Claeson, "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System," Blood Coagulation and Fibrinolysis (1994) 5, 411-436.
Colman et al., "Section A, Plasma Coagulation Factors," Plasma Coagulation Factors, 3-17.
Crabbe et al., "Acylated Plasminogen-Streptokinase Activator Complex: A New Approach to Thrombolytic Therapy," Pharmacotherapy (1990) 10:2, 115-126.
Davie, "Chapter 16, The Blood Coagulation Factors: Their cDNAs, Genes, and Expression," Plasma Coagulation Factors, Part 1, Section A, 242-268.
Di Scipio et al., "Activation of Human Factor X (Stuart Factor) by a Protoease from Russell's Viper Venom, Activation of Human Factor X," Biochemistry (1977) 16:24, 5253-5260.
Etingin et al., "Viral Activation of the Coagulation Cascade: Molecular Interactions at the Surface of Infected Endothelial Cells," Cell (1990) 61:657-662.
Fears, "Development of Anisoylated Plasminogen-Streptokinase Activator Complex from the Acyl Enzyme Concept," Seminars in Thrombosis and Hemostatsis (1980) 15:2, 129-139.
Fears et al., "The Protective Effect of Acylation on the Stability of Anisoylated Plasminogen Streptokinase Activator Complex in Human Plasma," Drugs (1987) 33 (Suppl. 3), 57-63.
Friedberg et al., "Large Scale Purification of Factor X by Hydrophobic Chromatography," Preparative Biochemistry (1988) 18:3, 303-320.
Furie et al., "The Molecular Basis of Blood Coagulation," Cell (1988) 53:505-518.
Gordon et al., "The Site of Activation of Factor X by Cancer Procoagulant," Blood Coagulation and Fibrinolyses (1991) 2:735-739.
Hoover et al., "The Adhesive Interaction between Polymorphonuclear Leukocytes and Endothelial Cells in Vitro," Cells (1978) 14: 423-428.
Hrinda et al., "Preclinical Studies of a Monoclonal Antibody-Purified Factor IX, Mononine.TM." Seminars in Hermatology (1991) 28:3, Suppl. 6 (Jul.), 6-14.
Jesty, "Analysis of the Generation and Inhibition of Activated Coagulation Factor X in Pure Systems and in Human Plasma," The Journal of Biological Chemistry (1986).
Kettner et al., "Synthesis of Peptides of Arginine Chloromethyl Ketone, Selective Inactivation of Human Plasma Kallikrien," Biochemistry (1978) 17:22, 4778-4783.
Kettner et al., "Active Site Mapping of Human and Rat Urinary Kallikreins by Peptidyl Chloromethyl Ketones," Archives Chloromethyl Ketones, Archives of Biochemistry and Biophysics (1980) 202:2, 420-430.
Kettner et al., "The Susceptibility of Urokinase to Affinity Labeling by Peptides of Arginine Chloromethy Ketone," Biochemica et Biophysica Acta (1979) 569:31-40.
Kettner et al., "Inactivation of Trypsin-Like Enzymes with Peptides of Arginine Chloromethyl Ketone," Methods in Enzymology (1981) 80:826-842.
Kettner et al., "The Selective Affinity Labeling of Factor X.sub.a by Peptides of Arginine Chloromethyl Ketone," Thrombosis Research (1981) 22:645-652.
Kosow, "Purification and Activation of Human Factor X: Cooperative Effect of Ca.sup.++ on the Activation Reaction," Thrombosis Research (1976) 9:565-573.
Lijnen et al., "Inhibition of Tryspin-Like Serine Proteinases by Tripeptide Arginyl and Lysyl Chloromethylketones," Thrombosis Research (1984) 34:431-437.
Marsh, "Snake Venoms Affecting the Haemosatic Mechanism --a Consideration of their Mechanisms, Practical Applications and Biological Significance," Blood Coagulation Fibrinolysis (1994) 5:399-410.
Mertens et al., "Pathways in the Activation of Human Coagulation Factor X," Biochem. J. (1980) 185:647-658.
Miletich et al., "The Synthesis of Sulfated Dextran Beads for Isolation of Human Plasma Coagulation Factors II, IX and X," Analytical Biochemistry, (1980) 105:304-310.
Monahan et al., "Identification of Human Cohn Fraction III as a Useful Source for the Simultaneous Purification of FIX and FX Zymogens," Thrombosis Research (1980) 19:743-755.
Nesheim et al., "The Contribution of Bovine Factor V and Factor Va to the Activity of Prothrombinase," The Journal of Biological Chemistry (1979) 254:21, 10952-10962.
Nesheim et al., "Confactor Dependence of Factor Xa Incorporation into the Prothrombinase Complex," The Journal of Biological Chemistry (1981) 256:13, 6537-6540.
Sinha et al., "Procoagulation Activities of Reversibly Acylated Forms of Factor Xa," Blood, (1995) 86:4153-4157.
Steinberg et al., "Activation of Factor X", Plasma Coagulation Factors, Part 1, Section A, Chapter 7, 112-119.
Sturzebecker, J. et al., "Acyl-Derivatives of tPA," Thrombosis Research (1987)47:6, 699-703 (first page missing).
Williams et al. , "Zymogen/Enzyme Discrimination Using Peptide Chloromethyl Ketones," The Journal of Biological Chemistry (1989) 264:13, 7536-7545.
Benedict et al. "Active Site-Blocked Factor Xa Prevents Thrombus Formation in the Coronary Vasculature in Parallel With Inhibition of Extravascular in a Canine Thrombosis Model," Blood (1993) 81:8, 2059-2066.
Furie et al., "Coagulant Protein of Russell' Viper Venom," Blood Clotting Enzymes, Methods in Enzymology, (1976) 45, 191-205.
COR Therapeutics Inc.
Degen Nancy
LandOfFree
Process for production of inhibited forms of activated blood fac does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for production of inhibited forms of activated blood fac, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for production of inhibited forms of activated blood fac will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1395482